Mounjaro

Mounjaro® is an injectable medication for the treatment of type 2 diabetes, developed by the global pharmaceutical company Eli Lilly and first approved in 2022.

Its active ingredient, tirzepatide, has gained worldwide recognition for its exceptional blood glucose-lowering efficacy and the significant weight loss observed in clinical trials. As a result, Mounjaro has become one of the most widely discussed and innovative therapies in metabolic medicine.